Fig. 3

Cancer detection pipeline (CDP) analyses of 41 cancer cases in this study. a Comparison of fraction of significant copy-number variation (FCNV) scores among 41 maternal malignancies cases, 501 non-cancer participants, and 1163 non–multiple chromosomal aneuploidies controls. The red line represents the cutoff of 0.22 to determine CDP positivity. Non–multiple chromosomal aneuploidies controls were 1163 pregnant women without multiple chromosomal aneuploidies results who were randomly selected from 1.93 million pregnant women who took a noninvasive prenatal screening (NIPS) test during the period for study eligibility. b Comparison of receiver operating characteristic curves (ROCs) for FCNV scores in one representative iteration of training and validation sets. c Comparison of FCNV scores in maternal malignancy patients at different cancer stages. d Correlation analysis between FCNV scores and the interval from NIPS tests to diagnosis of cancer in 39 cancer patients. The red line is a linear regression line between FCNV scores and the time from NIPS tests to diagnosis of cancer.